Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Conference Call March 13, 2024 4:30 PM ET
Company Participants
Michael Wood - Managing Director of LifeSci Advisors
Sath Shukla - CEO
Kamal Hamed - CMO
Esther Rajavelu - CFO and Chief Business Officer
Conference Call Participants
Ritu Baral - TD Cowen
Louise Chen - Cantor
Operator
Good afternoon and welcome to the Spero Therapeutics Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Following the company's formal remarks, we will open the call for questions. Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and further information related to today's announcements on the Spero Therapeutics website at sperotherapeutics.com.
At this time, I would like to turn the call over to Michael Wood, Managing Director of LifeSci Advisors. Mr. Wood, please go ahead.
Michael Wood
Thank you, operator, and thank you all for participating in today's conference call. This afternoon, Spero Therapeutics released financial results and provided a business update for the fourth quarter and full year 2023. Our press release is available on the Investor page of the Spero Therapeutics website.
Before we begin, I'd like to remind you that some of the information presented in this conference call contains forward-looking statements based on our current expectations, including statements about the future development and commercialization of Tebipenem HBr, SPR720, SPR206, and the design, initiation, timing, progress and results of the company's preclinical studies and clinical trials and its research and development programs. Management's assessment of the results of such preclinical studies and clinical trials, the company's cash forecast and anticipated expenses, and the sufficiency of its cash resources. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those contained in such statements.
Several factors that could cause or contribute to such differences are described in detail in Spero Therapeutics' filings with the SEC, including in the risk factors section of its annual report on Form 10-K for the year ended December 31, 2023, filed with the SEC today. These forward-looking statements speak only as of the date of this conference call, March 13, 2024. And the company undertakes no obligation to publicly update any forward-looking statements or supply new information regarding the company after the date of this call.
Participating today's call are Sath Shukla, Chief Executive Officer; Dr. Kamal Hamed, Chief Medical Officer; and Esther Rajavelu, Chief Financial and Chief Business Officer.